Coronavirus Vaccine Market, By Vaccine Type, By Distribution Channel, By Geography

Coronavirus Vaccine Market is estimated to be valued at USD 54.49 Bn in 2026 and is expected to reach USD 90.99 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.6% from 2026 to 2033.

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. COVID-19 is a viral infection caused by a coronavirus called SARS-CoV-2, which affects the respiratory tract. The COVID-19 is highly contagious and can be transmitted through direct contact with the infected person or indirect contact with surfaces in the immediate environment. Moreover, the number of people getting infected by COVID-19 has dynamically increased, making it a global pandemic. For instance, according to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 169 million cases and 3.5 million deaths due to coronavirus disease (COVID-19) were reported up till May 30, 2022 across the globe.

Market Dynamics

Market players are conducting clinical trials for developing more efficient vaccines against COVID-19, which could contribute to the growth of the market over the forecast period. For instance, in December, Zydus Cadila announced that ZyCoV-D vaccine cleared phase 1 and phase 2 trials. The company's plasmid DNA vaccine to prevent COVID-19, was found to be safe, well tolerated, and immunogenic in phase 1 and 2.

Market players are focusing on product launch and approvals, which is expected to strengthen their position in the global market. For instance, in December 2021, AstraZeneca's COVID-19 vaccine was approved for emergency supply in the U.K., with the first doses being released, so that vaccinations may begin by early 2022. The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) provided authorization for emergency supply of COVID-19 vaccine AstraZeneca, formerly AZD1222, for the active immunization of individuals 18 years or older. The authorization recommends two doses administered in an interval of between four and 12 weeks.

Market players are involved in inorganic growth strategies such as partnerships, collaborations, mergers, and acquisitions, in order to enhance distribution of COVID 19 vaccines. This is expected to drive the growth of the coronavirus vaccine market. For instance, on August 14, 2021, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) entered into an agreement with Moderna, Inc. to manufacture and deliver 100 million doses of COVID-19 vaccines produced by the company in the U.S. by 2022.

Key features of the study

• This report provides in-depth analysis of the global coronavirus vaccine market, and provides market size (US$ Bn) and compound annual growth rate (CAGR) (%) for the forecast period 2026 - 2033.
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, regional outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global coronavirus vaccine market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
• Key companies covered as a part of this study include Sinovac Biotech Ltd., Bharat Biotech International Limited, BioNTech SE, CanSinoBIO, CureVac AG, Zydus Cadila, AstraZeneca Plc, Arcturus Therapeutics Holdings Inc., Entos Pharmaceuticals, Symvivo, Novavax, Inc., Moderna, Inc., Johnson & Johnson, Sanofi S.A., Pfizer, Inc., and Serum Institute of India Pvt. Ltd.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansions and marketing tactics
• The global coronavirus vaccine market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global coronavirus vaccine market

Market Segmentation

• Global Coronavirus Vaccine Market, By Vaccine Type (Revenue, USD Bn, 2021 - 2033)
• Inactivated Virus
• Protein Subunit
• Non-replicating Viral Vector
• Repurposed Vaccines
• RNA Vaccine
• DNA Vaccine
• By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
• Government Channels
• Hospitals
• Clinics
• Others
• Global Coronavirus Vaccine Market, By Region (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles
• Pfizer-BioNtech
• AstraZeneca
• Bharat Biotech.
• Johnson & Johnson Services, Inc
• Moderna, Inc.
• Sinovac Biotech Ltd.
• Serum Institute of India Pvt. Ltd.
• Sanofi S.A.
• Novavax, Inc.
• Symvivo
• CanSinoBIO
• CureVac AG
• Zydus Cadila
• Arcturus Therapeutics Holdings Inc.
• Entos Pharmaceuticals
• GlaxoSmithKline
• EyeGene Inc.
• Arcturus Therapeutics
• Takara Bio